Millennium Management
IBRX icon

Millennium Management’s ImmunityBio IBRX Stock Holding History

Millennium Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$183K Buy
+23,800
New +$163K ﹤0.01% 5213
2024
Q2 		– Sell
-350,000
Closed -$1.88M – 6179
2024
Q1 		$1.88M Buy
+350,000
New +$1.58M ﹤0.01% 3799

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management's IBRX Position: Q1 2026 in Review

Millennium Management increased its ImmunityBio (IBRX) stake by 1,099% in Q1 2026, buying an estimated $8.91M and bringing the position to 1,420,244 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2094.

Millennium Management first reported a position in IBRX in Q1 2016 and has held it in 36 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Millennium Management held 1,420,244 shares of ImmunityBio worth $10.9M as of Q1 2026.
  • Millennium Management bought 1,301,816 ImmunityBio shares in Q1 2026, an estimated $8.91M.
  • ImmunityBio made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2094 holding.
  • Millennium Management first reported a position in ImmunityBio in Q1 2016 and has held it in 36 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.